Legend Biotech (LEGN) Non-Current Debt (2021 - 2025)

Legend Biotech (LEGN) has 5 years of Non-Current Debt data on file, last reported at $319.1 million in Q4 2025.

• In Q4 2025, Non-Current Debt rose 5.94% year-over-year to $319.1 million; the TTM figure through Dec 2025 stood at $319.1 million (up 5.94% YoY), while the FY2025 annual figure was $319.1 million, up 5.94% from the prior year.
• Non-Current Debt improved to $319.1 million in Q4 2025, from $142.9 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $319.1 million in Q4 2025 and bottomed at $17310.0 in Q2 2021.
• A 5-year average of $230.9 million and a median of $275.9 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt soared 116.61% — and 2025, when it plunged 51.83%.
• Year by year, Non-Current Debt stood at $120.5 million in 2021, then soared by 116.61% to $260.9 million in 2022, then gained by 7.82% to $281.3 million in 2023, then grew by 7.06% to $301.2 million in 2024, then grew by 5.94% to $319.1 million in 2025.
• The last three Non-Current Debt figures came in at $319.1 million (Q4 2025), $142.9 million (Q3 2025), and $310.3 million (Q2 2025), per Business Quant data.

Peer Comparison